Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcolonically Administered Adalimumab and Guselkumab in Healthy Adults
NCT07788807Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Nov 2026
01
Overview
Phase 1, open-label trial of SDL-001 in inflammatory bowel disease (IBD) (4 arms). Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 3 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SDL-001
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07788807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788807.